← Evidence map

ArticleCancers2025

Long-Term Immune Response to SARS-CoV-2 Vaccination in Hematologic Malignancies: An Update of the ImV-HOng Trial of the East German Study Group for Hematology and Oncology.

Susann Schulze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Long-Term Immune Response to SARS-CoV-2 Vaccination in Hematologic Malignancies: An Update of the ImV-HOng Trial of the East German Study Group for Hematology and Oncology. | OpenQuestion